These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1506265)

  • 1. A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogene-transformed NIH3T3 cells.
    Yoshida H; Sugita K
    Jpn J Cancer Res; 1992 Apr; 83(4):324-8. PubMed ID: 1506265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase.
    Kijima M; Yoshida M; Sugita K; Horinouchi S; Beppu T
    J Biol Chem; 1993 Oct; 268(30):22429-35. PubMed ID: 8226751
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents.
    Itazaki H; Nagashima K; Sugita K; Yoshida H; Kawamura Y; Yasuda Y; Matsumoto K; Ishii K; Uotani N; Nakai H
    J Antibiot (Tokyo); 1990 Dec; 43(12):1524-32. PubMed ID: 2276972
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological reversion of sis-transformed NIH3T3 cells by trichostatin A.
    Sugita K; Koizumi K; Yoshida H
    Cancer Res; 1992 Jan; 52(1):168-72. PubMed ID: 1727377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel compound, depudecin, induces production of transformation to the flat phenotype of NIH3T3 cells transformed by ras-oncogene.
    Sugita K; Yoshida H; Matsumoto M; Matsutani S
    Biochem Biophys Res Commun; 1992 Jan; 182(1):379-87. PubMed ID: 1731795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transformation-specific pattern of phosphorylation of c-Jun, Jun-B, Jun-D and Egr-1 in v-sis transformed cells.
    Grover-Bardwick A; Adamson E; Mercola D
    Carcinogenesis; 1994 Aug; 15(8):1667-74. PubMed ID: 8055649
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid, complete and reversible transformation by v-sis precedes irreversible transformation.
    Mercola D; Carpenter PM; Grover-Bardwick A; Mercola M
    Oncogene; 1992 Sep; 7(9):1793-803. PubMed ID: 1501889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversible transformation by v-sis: a model cell line for analysis of transformation by antisense methods.
    Carpenter PM; Mercola M; Mercola D
    Antisense Res Dev; 1991; 1(3):289-95. PubMed ID: 1821651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiproliferative effects of heparin on normal and transformed NIH/3T3 fibroblasts.
    Cavari S; Ruggiero M; Vannucchi S
    Cell Biol Int; 1993 Aug; 17(8):781-6. PubMed ID: 8106075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suramin enters and accumulates in low pH intracellular compartments of v-sis-transformed NIH 3T3 cells.
    Huang SS; Koh HA; Huang JS
    FEBS Lett; 1997 Oct; 416(3):297-301. PubMed ID: 9373173
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct involvement of cdc42 and RhoA GTPases in actin organization and cell shape in untransformed and Dbl oncogene transformed NIH3T3 cells.
    Olivo C; Vanni C; Mancini P; Silengo L; Torrisi MR; Tarone G; Defilippi P; Eva A
    Oncogene; 2000 Mar; 19(11):1428-36. PubMed ID: 10723134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase.
    Kwon HJ; Owa T; Hassig CA; Shimada J; Schreiber SL
    Proc Natl Acad Sci U S A; 1998 Mar; 95(7):3356-61. PubMed ID: 9520369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure of a new cyclotetrapeptide trapoxin A.
    Nakai H; Nagashima K; Itazaki H
    Acta Crystallogr C; 1991 Jul; 47 ( Pt 7)():1496-9. PubMed ID: 1930826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of glucocorticoids on oncogene transformed NIH3T3 cells.
    Matin A; Cheng KL; Suen TC; Hung MC
    Oncogene; 1990 Jan; 5(1):111-6. PubMed ID: 2181373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Imbalanced expression of cellular nuclear oncogenes caused by v-sis/PDGF-2.
    Sonobe MH; Bravo R; Armelin MS
    Oncogene; 1991 Sep; 6(9):1531-7. PubMed ID: 1923519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The v-sis oncoprotein loses transforming activity when targeted to the early Golgi complex.
    Hart KC; Xu YF; Meyer AN; Lee BA; Donoghue DJ
    J Cell Biol; 1994 Dec; 127(6 Pt 2):1843-57. PubMed ID: 7806564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Actin cytoskeleton polymerization in Dbl-transformed NIH3T3 fibroblasts is dependent on cell adhesion to specific extracellular matrix proteins.
    Defilippi P; Olivo C; Tarone G; Mancini P; Torrisi MR; Eva A
    Oncogene; 1997 Apr; 14(16):1933-43. PubMed ID: 9150360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intracellular retention of membrane-anchored v-sis protein abrogates autocrine signal transduction.
    Lee BA; Donoghue DJ
    J Cell Biol; 1992 Sep; 118(5):1057-70. PubMed ID: 1324943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autocrine mechanism for v-sis transformation requires cell surface localization of internally activated growth factor receptors.
    Fleming TP; Matsui T; Molloy CJ; Robbins KC; Aaronson SA
    Proc Natl Acad Sci U S A; 1989 Oct; 86(20):8063-7. PubMed ID: 2813378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
    Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
    Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.